Platelet-rich plasma (PRP) is a biological therapy that uses the patient’s own blood to obtain products with a higher platelet concentration than in blood. It provides a transient fibrin scaffold as a controlled drug delivery system of growth factors suitable for regenerative medicine. PRP has been used as medical strategy to treat diverse types of injuries in the field of orthopedics, including peripheral nerve lesions. In vitro and in vivo studies showed the neuroprotective, neurogenic and neuroinflammatory modulator effect of PRP. In addition, it has been demonstrated clinically that PRP infiltrations improve clinical symptoms and enhance the sensory and motor functional nerve muscle unit recovery. Potential effects of PRP could be applied in treatments for neuropathies, as conservative treatment by means of nerve ultrasound-guided infiltrations or as biological adjuvant during surgery.
In the last several years, global market of Plasma Therapy developed rapidly, with an average growth rate of 13.31% during 2014 to 2018. In 2018, global revenue of Plasma Therapy is nearly 197.1 M USD.
This report studies the Plasma Therapy market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
This report focuses on the global top players, covered
Market segment by Regions/Countries, this report covers:
Rest of Asia Pacific
Middle East & Africa
Central & South America
Market segment by Type, the product can be split into:
Leukocyte-rich Fibrin (L-PRF)
Market segment by Application, the market can be split into:
Cardiac Muscle Injury